Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer
Standard
Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. / Hartkopf, Andreas D; Müller, Volkmar; Wöckel, Achim; Lux, Michael P; Janni, Wolfgang; Nabieva, Naiba; Taran, Florin-Andrei; Ettl, Johannes; Lüftner, Diana; Belleville, Erik; Schütz, Florian; Fasching, Peter A; Fehm, Tanja N; Kolberg, Hans-Christian; Overkamp, Friedrich; Schneeweiss, Andreas; Tesch, Hans.
in: GEBURTSH FRAUENHEILK, Jahrgang 79, Nr. 3, 03.2019, S. 256-267.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer
AU - Hartkopf, Andreas D
AU - Müller, Volkmar
AU - Wöckel, Achim
AU - Lux, Michael P
AU - Janni, Wolfgang
AU - Nabieva, Naiba
AU - Taran, Florin-Andrei
AU - Ettl, Johannes
AU - Lüftner, Diana
AU - Belleville, Erik
AU - Schütz, Florian
AU - Fasching, Peter A
AU - Fehm, Tanja N
AU - Kolberg, Hans-Christian
AU - Overkamp, Friedrich
AU - Schneeweiss, Andreas
AU - Tesch, Hans
PY - 2019/3
Y1 - 2019/3
N2 - For many years, small but significant advancements have been made time and again in the prevention and treatment of early breast cancer. The so-called panel gene analyses are becoming more and more important in prevention, since the risk due to the tested genes is better understood and as a result, concepts for integration in health care can be developed. In the adjuvant situation, the first study in the so-called post-neoadjuvant situation was able to demonstrate a clear improvement in the prognosis with an absent pathological complete remission following trastuzumab or pertuzumab + trastuzumab. Additional studies with this post-neoadjuvant therapeutic concept are still being conducted at present. The CDK4/6 inhibitors which had shown a significant improvement in progression-free survival in a metastatic situation are currently being tested in the adjuvant situation in large therapeutic studies. These and other new data for the treatment or prevention of primary breast cancer are presented in this review against the backdrop of current studies.
AB - For many years, small but significant advancements have been made time and again in the prevention and treatment of early breast cancer. The so-called panel gene analyses are becoming more and more important in prevention, since the risk due to the tested genes is better understood and as a result, concepts for integration in health care can be developed. In the adjuvant situation, the first study in the so-called post-neoadjuvant situation was able to demonstrate a clear improvement in the prognosis with an absent pathological complete remission following trastuzumab or pertuzumab + trastuzumab. Additional studies with this post-neoadjuvant therapeutic concept are still being conducted at present. The CDK4/6 inhibitors which had shown a significant improvement in progression-free survival in a metastatic situation are currently being tested in the adjuvant situation in large therapeutic studies. These and other new data for the treatment or prevention of primary breast cancer are presented in this review against the backdrop of current studies.
U2 - 10.1055/a-0842-6614
DO - 10.1055/a-0842-6614
M3 - SCORING: Journal article
C2 - 30880824
VL - 79
SP - 256
EP - 267
JO - GEBURTSH FRAUENHEILK
JF - GEBURTSH FRAUENHEILK
SN - 0016-5751
IS - 3
ER -